Effect of angiotensin II type 1 receptor blockade on conduit artery tone in subtotally nephrectomized rats

Nephron - Physiology

Volumn 96, Issue 3, 2004, Pages

  Kööbi, Peeter ^a   Jolma, Pasi ^a   Kalliovalkama, Jarkko ^a,b   Tikkanenf, Ilkka ^c,d   Fan, Meng ^a   Kähönen, Mika ^a,b   Moilanen, Eeva ^a   Pörsti, Ilkka ^a,c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

Arterial smooth muscle; At1 receptor; Conductance vessels; Endothelium; Potassium channels; Renal failure

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ION; CREATININE; LEMAKALIM; LOSARTAN; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY TONE; ARTICLE; AUTORADIOGRAPHY; BLOOD CHEMISTRY; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG RECEPTOR BINDING; HORMONE RECEPTOR INTERACTION; ISOLATED ARTERY; KIDNEY FAILURE; MALE; NEPHRECTOMY; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; STATISTICAL SIGNIFICANCE; URINALYSIS; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; KIDNEY; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MESENTERIC ARTERIES; NEPHRECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; VASOCONSTRICTION; VASODILATION;

EID: 1842611573     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076754     Document Type: Article

References (34)

1. London GM: Alterations of arterial function in end-stage renal disease. Nephron 2000;84:111-118.
2. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-2439.
3. Amann K, Wolf B, Nichols C, Tornig J, Schwarz U, Zeier M, Mall G, Ritz E: Aortic changes in experimental renal failure: Hyperplasia or hypertrophy of smooth muscle cells? Hypertension 1997;29:770-775.
4. Hafner J, Keusch G, Wahl C, Sauter B, Hurlimann A, von Weizsäcker F, Krayenbühl M, Biedermann K, Brunner U, Helfenstein U: Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): A complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 1995;33:954-962.
5. Rabelink TJ, Koomans HA: Endothelial function and the kidney. An emerging target for cardiovascular therapy. Drugs 1997;53:11-19.
6. Van Guldener C, Lambert J, Janssen MJ, Donker AJ, Stehouwer CD: Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 1997;12:14-18.
7. Kalliovalkama J, Jolma P, Tolvanen JP, Kähönen M, Hutri-Kähönen N, Saha H, Tuorila S, Moilanen E, Pörsti I: Potassium channelmediated vasorelaxation is impaired in experimental renal failure. Am J Physiol 1999;277:H1622-H1629.
8. Plum J, Bunten B, Nemeth R, Grabensee B: Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998;9:2223-2234.
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
10. Noda M, Matsuo T, Fukuda R, Ohta M, Nagano H, Shibouta Y, Naka T, Nishikawa K, Imura Y: Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int 1999;56:898-909.
11. Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653-1659.
12. 1 receptor blockade improves vasorelaxation in experimental renal failure. Hypertension 2003;41:1364-1371.
13. Arvola P, Pörsti I, Vuorinen P, Pekki A, Vapaatalo H: Contractions induced by potassiumfree solution and potassium relaxation in vascular smooth muscle of hypertensive and normotensive rats. Br J Pharmacol 1992;106:157-165.
14. Plane F, Holland M, Waldron GJ, Garland CJ, Boyle JP: Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br J Pharmacol 1997;121:1509-1511.
15. Kung CF, Luscher TF: Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995;25:194-200.
16. Bäcklund T, Palojoki E, Grönholm T, Eriksson A, Vuolteenaho O, Laine M, Tikkanen I: Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo. Pharmacol Res 2001;44:411-418.
17. Zhuo J, Alcorn D, Allen AM, Mendelsohn FA: High-resolution localization of angiotensin II receptors in rat renal medulla. Kidney Int 1992;42:1372-1380.
18. Buikema H, Monnink SH, Tio RA, Crijns HJ, de Zeeuw D, van Gilst WH: Comparison of zofenopril and lisinopril to study the role of the sulfhydryl group in improvement of endothelial dysfunction with ACE inhibitors in experimental heart failure. Br J Pharmacol 2000;130:1999-2007.
19. Esquerro E, Rivas-Cabanero L, Lopez-Novoa JM: Glomerular angiotensin II receptors in gentamicin-induced renal failure in the rat. Ren Fail 1995;17:689-694.
20. Schiffrin EL: Resistance arteries as endpoints in hypertension. Blood Press Suppl 1997;2:24-30.
21. Ferro CJ, Haynes WG, Hand MF, Webb DJ: Forearm vasoconstriction to endothelin-1 is impaired, but constriction to sarafotoxin 6c and vasodilatation to BQ-123 unaltered, in patients with essential hypertension. Clin Sci (Lond) 2002;103(suppl 48):53-58.
22. Hand MF, Haynes WG, Webb DJ: Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure. Nephrol Dial Transplant 2001;16:295-301.
23. Lariviere R, D'Amours M, Lebel M, Kingma I, Grose JH, Caron L: Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass. Kidney Blood Press Res 1997;20:372-380.
24. 2 analogue in aortic rings from spontaneously hypertensive rats: Role of nitric oxide. J Hypertens 1997;15:1677-1684.
25. Lariviere R, Lebel M, Kingma I, Grose JH, Boucher D: Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am J Hypertens 1998;11:989-997.
26. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN: Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000;83:205-209.
27. Morris ST, McMurray JJ, Rodger RS, Jardine AG: Impaired endothelium-dependent vasodilatation in uraemia. Nephrol Dial Transplant 2000;15:1194-1200.
28. Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131-185.
29. Cohen RA, Vanhoutte PM: Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995;92:3337-3349.
30. Hayabuchi Y, Davies NW, Standen NB: Angiotensin II inhibits rat arterial KATP channels by inhibiting steady-state protein kinase A activity and activating protein kinase Ce. J Physiol 2001;530:193-205.
31. Dimitropoulou C, White RE, Fuchs L, Zhang H, Catravas JD, Carrier GO: Angiotensin II relaxes microvessels via the AT(2) receptor and Ca(2+)- activated K(+) (BK(Ca)) channels. Hypertension 2001;37:301-307.
32. Wagner L, Klein JD, Sands JM, Baylis C: Urea transporters are distributed in endothelial cells and mediate inhibition of L-arginine transport. Am J Physiol Renal Physiol 2002;283:F578-F582.
33. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
34. Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJ: Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 1993;267:657-663.